InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that the Company will be participating in the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025, in New York. During the conference, members of InMed's management team will also be conducting one-on-one meetings with investors. Additionally a corporate presentation from the Company will be available online.

In the presentation, Mr. Michael Woudenberg, InMed's Chief Operating Officer, will highlight updates and progress of InMed's pipeline including recent data from the Company's leading pharmaceutical program INM-901 in the treatment of Alzheimer's, that was recently presented at Alzheimer's Association International Conference (AAIC) 2025, the world's leading forum for Alzheimer's disease and dementia research.

H.C. Wainwright 27th Annual Global Investment Conference
Presentation Link: https://journey.ct.events/view/09f2e465-e7f2-45b7-83d6-e1fb4303ebc4

The webcast will be available for 90 days at the link above or on the InMed Investor Relations Events page: https://www.inmedpharma.com/investors/events/

About InMed:

InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.

Investor Contact:

Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.com

Cautionary Note Regarding Forward-Looking Information:

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: a corporate presentation highlighting recent updates and progress with InMed's pipeline including recent data from the Company's lead program INM-901 in the treatment of Alzheimer's

Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, in Item 1A. of the Quarterly Report for the period ended March 31, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265322

News Provided by Newsfile via QuoteMedia

INM
The Conversation (0)
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

  • Advances INM-901 program, addressing multiple key biological pathways implicated in Alzheimer's disease pathology

  • Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

  • Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that Eric A. Adams, InMed's CEO, will present live at the Life Sciences Virtual Investor Forum hosted by VirtualInvestorConferences.com, on September 18th, 2025.

DATE : September 18 th
TIME: 2:00 PM ET
LINK: REGISTER HERE
Available for 1x1 meetings: September 18-23. Please schedule 1x1 meetings here.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Life Science Virtual Investor Forum Agenda Announced for September 18th

Life Science Virtual Investor Forum Agenda Announced for September 18th

Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Science Virtual Investor Forum to be held September 18th. This event is co-hosted by Zacks SCR.

Individual investors, institutional investors, advisors, and analysts are invited to attend.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
InMed to Present INM-901 Data at Alzheimer's Association International Conference  2025

InMed to Present INM-901 Data at Alzheimer's Association International Conference 2025

Long-term INM-901 treatment in preclinical studies in advanced disease continues to show multi-modal activity

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it is presenting new preclinical data from its INM-901 program at the upcoming Alzheimer's Association International Conference (AAIC) 2025, the world's leading forum for Alzheimer's disease ("AD") and dementia research.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the closing of its previously announced private placement priced at-the-market under Nasdaq rules for the issuance and sale of 1,952,363 of its common shares (or pre-funded warrants in lieu thereof) and short-term preferred investment options to purchase up to an aggregate of 1,952,363 common shares, at a purchase price of $2.561 per share (or pre-funded warrant in lieu thereof) and associated short-term preferred investment option. The short-term preferred investment option issued in the offering is exercisable immediately upon issuance at an exercise price of $2.436 per share and will expire eighteen months from the effective date of the Resale Registration Statement (as defined below).

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News